* . *
  • About
  • Advertise
  • Privacy & Policy
  • Contact
Thursday, July 31, 2025
Earth-News
  • Home
  • Business
  • Entertainment
    Sens. Blackburn, Warnock introduce CREATE Act to provide tax relief to music creators – Yahoo Home

    Sens. Blackburn and Warnock Launch CREATE Act to Deliver Tax Relief for Music Creators

    That’s (Political) Entertainment: When Theatre Meets Politics

    Future Script: How Generative AI Is Changing Collective Bargaining in the Entertainment Industry – Jackson Lewis

    Future Script: How Generative AI Is Transforming Collective Bargaining in Entertainment

    The SBA’s live-entertainment bailout was supposed to end two years ago. We still don’t know how $1.5 billion was spent. – Yahoo Home

    $1.5 Billion Live-Entertainment Bailout: Two Years Later, Where Did the Money Go?

    Wall Street Bets: Caesars, Golden Entertainment, Churchill Downs, GLPI, Boyd – CDC Gaming

    Top Wall Street Bets: Caesars, Golden Entertainment, Churchill Downs, GLPI, and Boyd Take Center Stage

    Micro wrestling coming to NE Ohio – Cleveland.com

    Get Ready, NE Ohio: Micro Wrestling Is Making Its Exciting Debut!

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Cognizant Technology Solutions Corp (CTSH) Q2 2025 Earnings Call Highlights: Strong Revenue … – Yahoo.co

    Cognizant Q2 2025 Earnings: Impressive Revenue Growth and Key Takeaways

    Revving Up The U.S. Technology Engine – Forbes

    Revving Up The U.S. Technology Engine – Forbes

    More than just a hockey player – Rochester Institute of Technology Athletics

    Beyond the Ice: The Inspiring Journey of a Remarkable Athlete from Rochester Institute of Technology

    Smart Logistics in Warehousing – From Legacy Protocols to Green IoT – How Technology Is Reshaping the Sustainable Supply Chain – Logistics Viewpoints –

    Smart Logistics in Warehousing – From Legacy Protocols to Green IoT – How Technology Is Reshaping the Sustainable Supply Chain – Logistics Viewpoints –

    AI’s race in the dark with China – Axios

    The High-Stakes AI Race: Innovation and Competition in the Shadows

    Eagle Unveils Revolutionary X-Ray Technology at Pack Expo

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
  • Home
  • Business
  • Entertainment
    Sens. Blackburn, Warnock introduce CREATE Act to provide tax relief to music creators – Yahoo Home

    Sens. Blackburn and Warnock Launch CREATE Act to Deliver Tax Relief for Music Creators

    That’s (Political) Entertainment: When Theatre Meets Politics

    Future Script: How Generative AI Is Changing Collective Bargaining in the Entertainment Industry – Jackson Lewis

    Future Script: How Generative AI Is Transforming Collective Bargaining in Entertainment

    The SBA’s live-entertainment bailout was supposed to end two years ago. We still don’t know how $1.5 billion was spent. – Yahoo Home

    $1.5 Billion Live-Entertainment Bailout: Two Years Later, Where Did the Money Go?

    Wall Street Bets: Caesars, Golden Entertainment, Churchill Downs, GLPI, Boyd – CDC Gaming

    Top Wall Street Bets: Caesars, Golden Entertainment, Churchill Downs, GLPI, and Boyd Take Center Stage

    Micro wrestling coming to NE Ohio – Cleveland.com

    Get Ready, NE Ohio: Micro Wrestling Is Making Its Exciting Debut!

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Cognizant Technology Solutions Corp (CTSH) Q2 2025 Earnings Call Highlights: Strong Revenue … – Yahoo.co

    Cognizant Q2 2025 Earnings: Impressive Revenue Growth and Key Takeaways

    Revving Up The U.S. Technology Engine – Forbes

    Revving Up The U.S. Technology Engine – Forbes

    More than just a hockey player – Rochester Institute of Technology Athletics

    Beyond the Ice: The Inspiring Journey of a Remarkable Athlete from Rochester Institute of Technology

    Smart Logistics in Warehousing – From Legacy Protocols to Green IoT – How Technology Is Reshaping the Sustainable Supply Chain – Logistics Viewpoints –

    Smart Logistics in Warehousing – From Legacy Protocols to Green IoT – How Technology Is Reshaping the Sustainable Supply Chain – Logistics Viewpoints –

    AI’s race in the dark with China – Axios

    The High-Stakes AI Race: Innovation and Competition in the Shadows

    Eagle Unveils Revolutionary X-Ray Technology at Pack Expo

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
Earth-News
No Result
View All Result
Home Health

High Response Rates With Gene Therapies for BCG-Unresponsive Bladder Cancer

May 5, 2024
in Health
High Response Rates With Gene Therapies for BCG-Unresponsive Bladder Cancer
Share on FacebookShare on Twitter

SAN ANTONIO — More than 70% of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) achieved complete responses to a novel gene therapy, a small preliminary trial showed.

Across a range of doses, 16 of 22 patients had a complete response to detalimogene voraplasmid (EG-70), including 15 at 3 months and 10 at 6 months. Additionally, seven of 10 patients treated with the recommended phase II dose had complete responses. A majority of the responses persisted for 3-6 months.

About half of patients had treatment-related adverse events (TRAEs), only one of which reached grade 3 severity, reported Gordon Brown, DO, of Summit Health in Voorhees, New Jersey, at the American Urological Association annual meeting.

“Interim data from the phase I portion of the LEGEND study suggest a promising safety, tolerability, and efficacy profile,” said Brown. “Reported TRAEs are mostly grade 1/2 and consistent with catheterization/intravesical administration. As a noninfective gene therapy, there are no special handling precautions, patient restrictions post-treatment or ultra-cold chain logistics considerations. The treatment was delivered effectively and easily within our clinics, using our existing infrastructure without burdensome changes.”

Updated trial results for an adenoviral oncolytic gene therapy continued to show promising safety and efficacy. Cretostimogene grenadenorepvec led to complete responses in three-fourths of 105 evaluable patients with BCG-unresponsive NMIBC. Among patients followed for at least a year, more than 80% of the responses lasted at least 12 months, reported Mark Tyson, MD, of the Mayo Clinic in Scottsdale, Arizona.

NMIBC accounts for about 80% of all newly diagnosed bladder cancers, and about 30% of the cases have high-risk features. Intravesical instillation of BCG is standard of care for high-risk patients, but the disease recurs or progresses in half of cases (BCG unresponsive). Patients with recurrent/progressive disease have limited options beyond radical cystectomy, which remains standard of care to prevent progression to muscle-invasive bladder cancer, Brown noted in his introductory comments.

EG-70 is a nonintegrating, nonviral gene therapy designed for administration in any urology clinic. The therapy has a simplified preparation and administration process and requires no specialized storage or handling, reducing treatment burden for patients and clinic personnel, he continued.

EG-70 has a unique delivery vehicle containing a DNA plasmid that encodes retinoic acid-inducible gene (RIG) 1 agonist and interleukin (IL)-12. Administered intravesically, the gene therapy transfects and stimulates the immune system in the bladder.

The RIG-1 agonist stimulates NK cells and suppressor cell attenuation to promote tumor killing and also stimulates T-cell recruitment and neo-antigen presentation, Brown explained. IL-12 activates T-cell dependent cytokine response to promote tumor killing and immune memory. Bladder-restricted production has the potential to drive a strong therapeutic effect while reducing the potential for systemic adverse events.

The phase I component of the LEGEND trial included 24 patients (22 evaluable for response), who received two or four doses of EG-70 per 12-week cycle. The primary endpoint was safety, and the secondary endpoint was efficacy at 3 months.

Laboratory studies showed dose-dependent levels of IL-12 protein in the urine of every patient but no clinically significant levels in plasma.

The safety profile of all 24 patients showed that TRAEs occurred in 13 patients, and all but one TRAE was grade 1 or 2. The only grade 3 TRAE was renal failure, which occurred in a patient with a history of renal failure. The most common TRAEs (any grade) were hematuria (12.5%), dysuria (12.5%), and micturition urgency, fatigue, nocturia, and pyrexia (8.3% each).

The efficacy results showed a 3-month complete response rate of 68% (70% in patients who received the recommended phase II dose). Brown said 11 of 15 complete responses at 3 months persisted for at least 3 months, including six of seven responses with the recommended phase II dose.

Enrollment in the phase II component of the study has begun, with an accrual target of 100 patients. Patients will receive four doses of EG-70 at weeks 1, 2, 5, and 8 of a 12-week cycle.

Results after enrollment of 105 patients in the BOND-003 trial of cretostimogene remained consistent with earlier reports after 34 patients and 66 patients. The latest results showed complete responses in 79 (75%) patients at any time during follow-up. Additionally, responses persisted for 12 moths or longer in 29 of 35 (83%) responding patients followed for at least a year, said Tyson.

The results with single-agent cretostimogene compared favorably with those of the CORE-001 trial that combined the gene therapy with pembrolizumab (Keytruda). The combination led to complete responses in 29 of 34 (85%) patients, and 14 of 16 (88%) patients followed for a year had a response duration ≥12 months. Results from other recent trials of novel therapies for BCG-unresponsive bladder cancer showed complete responses in 41-62% of patients.

The collective results with cretostimogene suggest the gene therapy has the potential to become backbone therapy in NMIBC, according to Tyson.

author['full_name']

Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined MedPage Today in 2007. Follow

Disclosures

The LEGEND study was supported by enGene.

Brown disclosed relationships with Astellas, Bayer, enGene, Janssen, mdxhealth, Sumitomo, Ferring, Lantheus, Novartis, Pfizer, UroGPO, and Veracyte.

BOND-003 was supported by CG Oncology.

Tyson disclosed no relationships with industry.

Primary Source

American Urological Association

Source Reference: Kalota S, et al “LEGEND: A phase I/II study of EG-70 (detalimogene voraplasmid), a novel, nonviral intravesical gene therapy for patients with BCG-unresponsive non-muscle invasive ladder cancer with carcinoma in situ” AUA 2024; Abstract P2-08.

Secondary Source

American Urological Association

Source Reference: Tyson MD, et al “Pivotal results from BOND-003: A single-arm study of intravesical cretostimogene grenadenorepvec for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ” AUA 2024; Abstract P2-02.

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : MedPageToday – https://www.medpagetoday.com/meetingcoverage/aua/109967

Tags: healthRatesResponse
Previous Post

What Do New Breast Cancer Screening Recs Say?

Next Post

No PSA Recurrence at 24 Months With Apalutamide Plus ADT After Radical Prostatectomy

New DNA Analysis Allows Scientists To Identify Specific Animals by Their Feces – Smithsonian Institution

Breakthrough DNA Analysis Enables Scientists to Identify Animals Just from Their Feces

July 31, 2025
Some killer whales hunt in pairs to maximize their bounty – Science News

Some killer whales hunt in pairs to maximize their bounty – Science News

July 31, 2025
Be Like Blippi Week – Adventure Science Center

Join the Fun: Be Like Blippi Week at Adventure Science Center!

July 31, 2025
Martha Stewart questions Meghan Markle’s lifestyle brand: ‘Hope she knows what she’s talking about’ – Page Six

Martha Stewart Raises Eyebrows Over Meghan Markle’s Lifestyle Brand: “Hope She Knows What She’s Talking About

July 31, 2025
Trump Executive Order Ends De Minimis Exemption for Rest of World – The New York Times

Trump Executive Order Ends De Minimis Exemption for Rest of World – The New York Times

July 31, 2025
Mexico’s economy grew 0.7% in Q2, outpacing analysts’ forecasts – Mexico News Daily

Mexico’s economy grew 0.7% in Q2, outpacing analysts’ forecasts – Mexico News Daily

July 31, 2025
Sens. Blackburn, Warnock introduce CREATE Act to provide tax relief to music creators – Yahoo Home

Sens. Blackburn and Warnock Launch CREATE Act to Deliver Tax Relief for Music Creators

July 31, 2025
Malnutrition rates reach alarming levels in Gaza, WHO warns – World Health Organization (WHO)

Malnutrition rates reach alarming levels in Gaza, WHO warns – World Health Organization (WHO)

July 31, 2025
Ahead of Trade Deadline, Trump Threatens Canada for Backing Palestinian State – The New York Times

Trump Delivers Stark Warning to Canada Over Backing Palestinian State Ahead of Trade Deadline

July 31, 2025
Cognizant Technology Solutions Corp (CTSH) Q2 2025 Earnings Call Highlights: Strong Revenue … – Yahoo.co

Cognizant Q2 2025 Earnings: Impressive Revenue Growth and Key Takeaways

July 31, 2025

Categories

Archives

July 2025
MTWTFSS
 123456
78910111213
14151617181920
21222324252627
28293031 
« Jun    
Earth-News.info

The Earth News is an independent English-language daily published Website from all around the World News

Browse by Category

  • Business (20,132)
  • Ecology (747)
  • Economy (772)
  • Entertainment (21,652)
  • General (16,209)
  • Health (9,809)
  • Lifestyle (780)
  • News (22,149)
  • People (774)
  • Politics (781)
  • Science (15,985)
  • Sports (21,269)
  • Technology (15,751)
  • World (755)

Recent News

New DNA Analysis Allows Scientists To Identify Specific Animals by Their Feces – Smithsonian Institution

Breakthrough DNA Analysis Enables Scientists to Identify Animals Just from Their Feces

July 31, 2025
Some killer whales hunt in pairs to maximize their bounty – Science News

Some killer whales hunt in pairs to maximize their bounty – Science News

July 31, 2025
  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

Go to mobile version